Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biotime Inc (BTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 324,878
  • Shares Outstanding, K 110,880
  • Annual Sales, $ 5,920 K
  • Annual Income, $ 33,570 K
  • 36-Month Beta 2.12
  • Price/Sales 54.47
  • Price/Cash Flow 0.00
  • Price/Book 1.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +5.00%
on 07/18/17
3.21 -8.41%
on 06/30/17
unch (unch)
since 06/20/17
3-Month
2.80 +5.00%
on 07/18/17
3.50 -16.00%
on 06/13/17
-0.23 (-7.26%)
since 04/20/17
52-Week
2.67 +10.11%
on 09/06/16
4.01 -26.68%
on 09/26/16
-0.06 (-2.00%)
since 07/20/16

Most Recent Stories

More News
BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release second...

BTX : 2.94 (+0.34%)
Data From BioTime's Phase I/IIa OpRegen(R) Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to...

BTX : 2.94 (+0.34%)
BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion...

BTX : 2.94 (+0.34%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioTime, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

BTX : 2.94 (+0.34%)
BioTime's Renevia(R) Achieves Primary Endpoint in European Pivotal Trial

--• BioTime on Track to File for Renevia CE Mark by End of 2017

BTX : 2.94 (+0.34%)
BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics' Strategic Investment Conference on May 24

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer...

BTX : 2.94 (+0.34%)
Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1

Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago...

GALE : 0.58 (+2.44%)
BTX : 2.94 (+0.34%)
INFI : 1.41 (-1.40%)
CPRX : 3.05 (+4.10%)
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

GALE : 0.58 (+2.44%)
BTX : 2.94 (+0.34%)
ECYT : 1.42 (-0.70%)
INFI : 1.41 (-1.40%)
BioTime Presents Retinal Restoration Data at ARVO

--Tissue is Highly Similar to Natural Human Tissue

BTX : 2.94 (+0.34%)
BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for...

BTX : 2.94 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body....

See More

Support & Resistance

2nd Resistance Point 3.03
1st Resistance Point 2.98
Last Price 2.94
1st Support Level 2.87
2nd Support Level 2.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.